Cash Flow Halozyme Therapeutics, Inc. Cash flow Statement
Figures in Million
Consolidated Cash Flow Results
Dec'25
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
No of Months
12
12
12
12
12
12
Profit Before Tax
466.00
557.00
348.00
248.00
248.00
129.00
Adjustment
0.00
0.00
0.00
0.00
0.00
0.00
Changes In working Capital
-152.00
-89.00
-38.00
-85.00
3.00
-108.00
Cash Flow after changes in Working Capital
0.00
0.00
0.00
0.00
0.00
0.00
Cash Flow from Operating Activities
651.00
479.00
388.00
240.00
299.00
55.00
Cash Flow from Investing Activities
-545.00
-262.00
-96.00
-487.00
-406.00
78.00
Cash Flow from Financing Activities
-85.00
-218.00
-407.00
362.00
77.00
-106.00
Net Cash Inflow / Outflow
20.00
-2.00
-116.00
115.00
-28.00
27.00
Opening Cash & Cash Equivalents
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
0.00
0.00
0.00
0.00
0.00
0.00
Figures in USD Million
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Halozyme Therapeutics, Inc.
Figures in Million
consolidated Cash Flow Results
Change(USD)
Change(%)
Profit Before Tax
466.875
-224
690.00
308.43%
Adjustment
0
0
0.00
0.00%
Changes In working Capital
-152.256
99
-251.00
-253.79%
Cash Flow after changes in Working Capital
0
0
0.00
0.00%
Cash Flow from Operating Activities
651.558
560
91.00
16.35%
Cash Flow from Investing Activities
-545.813
-279
-266.00
-95.63%
Cash Flow from Financing Activities
-85.174
-275
190.00
69.03%
Net Cash Inflow / Outflow
20.571
77
-57.00
-73.28%
Opening Cash & Cash Equivalents
0
0
0.00
0.00%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
71
-71.00
-100.00%
Closing Cash & Cash Equivalent
0
0
0.00
0.00%
Cash Flow - Snapshot (Consolidated) - Dec'25
YoY Growth in year ended Dec 2025 is 36.01% vs 23.29% in Dec 2024
Dec'25
Dec'24
Change(%)
Cash Flow from Operating Activities
651.56
479.06
36.01%
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
